The gut barrier: New acquisitions and therapeutic approaches

Journal of Clinical Gastroenterology

Volumn 46, Issue SUPPL. 1, 2012, Pages

  Scaldaferri, Franco ^a   Pizzoferrato, Marco ^a   Gerardi, Viviana ^a   Lopetuso, Loris ^a   Gasbarrini, Antonio ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

barrier; breath test; gut; microbiota; permeability

Indexed keywords

BISMUTH; CORTICOSTEROID; EDETIC ACID; LACTULOSE; MACROGOL 400; MANNITOL; MESALAZINE; PROBIOTIC AGENT; RHAMNOSE; SUCRALFATE;

ARTICLE; CELL STRAIN CACO 2; CELL STRAIN HT29; CROHN DISEASE; ENTERITIS; ENTEROCOLITIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTESTINAL BARRIER; INTESTINE EPITHELIUM CELL; INTESTINE FLORA; INTESTINE MUCOSA; INTESTINE MUCOSA PERMEABILITY; NONHUMAN; PEPTIC ULCER; PRIORITY JOURNAL; ULCERATIVE COLITIS;

CACO-2 CELLS; EPITHELIAL CELLS; HT29 CELLS; HUMANS; INTESTINAL ABSORPTION; INTESTINAL DISEASES; INTESTINAL MUCOSA; INTESTINES; PERMEABILITY;

EID: 84866237041     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31826ae849     Document Type: Article

References (75)

1. Bjarnason I, MacPherson A, Hollander D. Intestinal permeability: an overview. Gastroenterology. 1995;108:1566-1581.
2. Jung C, Hugot JP, Barreau F. Peyer's patches: the immune sensors of the intestine. Int J Inflam. 2010;2010:823710.
3. Canani RB, Terrin G. Gastric acidity inhibitors and the risk of intestinal infections. Curr Opin Gastroenterol. 2010;26:31-35.
4. Backhed F, Ley RE, Sonnenburg JL, et al. Host-bacterial mutualism in the human intestine. Science. 2005;307:1915-1920. (Pubitemid 40404694)
5. Sekirov I, Russell SL, Antunes LC, et al. Gut microbiota in health and disease. Physiol Rev. 2010;90:859-904.
6. Searle LE, Best A, Nunez A, et al. A mixture containing galactooligosaccharide, produced by the enzymic activity of Bifidobacterium bifidum, reduces Salmonella enterica serovar Typhimurium infection in mice. J Med Microbiol. 2009;58(Pt 1): 37-38.
7. Silva AM, Barbosa FH, Duarte R, et al. Effect of Bifidobacterium longum ingestion on experimental salmonellosis in mice. J Appl Microbiol. 2004;97:29-37. (Pubitemid 38869879)
8. Truusalu K, Mikelsaar R-H, Naaber P, et al. Eradication of Salmonella Typhimurium infection in a murine model of typhoid fever with the combination of probiotic Lactobacillus fermentum ME-3 and ofloxacin. BMC Microbiol. 2008;8:132.
9. Sonnenburg ED, Zheng H, Joglekar P, et al. Specificity of polysaccharide use in intestinal bacteroides species determines diet-induced microflora alterations. Cell. 2010;141:1241-1252.
10. Martens EC, Roth R, Heuser JE, et al. Coordinate regulation of glycan degradation and polysaccharide capsule biosynthesis by a prominent gut symbiont. J. Biol. Chem. 2009;284:18445-18457.
11. Burger van Paassen N, Vincent A, Puiman PJ, et al. The regulation of intestinal mucin MUC2 expression by short chain fatty acid: implications for epithelial protection. Biochem J. 2009;420:211-219.
12. Dharmani P, Srivastava V, Kissoon-Singh V, et al. Role of intestinal mucins in innate host defense mechanisms against pathogens. J Innate Immun. 2009;1:123-135.
13. Kim Y, Kim SH, Whang KY, et al. Inhibition of Escherichia coli O157:H7 attachment by interactions between lactic acid bacteria and intestinal epithelial cells. J Microbiol Biotechnol. 2008;18:1278-1285.
14. Mack DR, Ahrne S, Hyde L, et al. Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut. 2003;52:827-833. (Pubitemid 36613489)
15. Galdeano CM, Perdigon G. The probiotic bacterium Lactobacillus casei induces activation of the gut mucosal immune system through innate immunity. Clin Vaccine Immunol. 2006;13:219-226. (Pubitemid 43383790)
16. Leblanc J, Fliss I, Matar C. Induction of a humoral immune response following an Escherichia coli O157:H7 infection with an immunomodulatory peptidic fraction derived from Lactobacillus helveticus-fermented milk. Clin Diagn Lab Immunol. 2004;11:1171-1181. (Pubitemid 39540862)
17. Frank DN, St Amand AL, Feldman RA, et al. Molecularphylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA. 2007;104:13780-13785. (Pubitemid 350003397)
18. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology. 2002;122: 44-54. (Pubitemid 34049193)
19. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008;134:577-594. (Pubitemid 351173057)
20. Johansson ME, Larsson JM, Hansson GC. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. Proc Natl Acad Sci USA. 2010;108(suppl 1):4659-4665.
21. Lang T, Hansson GC, Samuelsson T. Gel-forming mucins appeared early in metazoan evolution. Proc Natl Acad Sci USA. 2007;104:16209-16214. (Pubitemid 350099386)
22. Kitajima S, Takuma S, Morimoto M. Histological analysis of murine colitis induced by dextran sulfate sodium of different molecular weights. Exp Anim. 2000;49:9-15.
23. Johansson ME, Gustafsson JK, Sjoberg KE, et al. Bacteria penetrate the inner mucus layer before inflammation in the dextran sulfate colitis model. PLoS One. 2010;5:e12238.
24. Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol. 2009;9:799-809.
25. JohanssonME, PhillipsonM, Petersson J, et al. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci USA. 2008;105:15064-15069.
26. Velcich A, Yang W, Heyer J, et al. Colorectal cancer in mice genetically deficient in the mucin Muc2. Science. 2002;295: 1726-1729. (Pubitemid 34202910)
27. Van der Sluis M, De Koning BA, De Bruijn AC, et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology. 2006;131:117-129. (Pubitemid 44015753)
28. Groschwitz KR, Hogan SP. Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol. 2009;124.
29. Roda G, Sartini A, Zambon E, et al. Intestinal epithelial cells in inflammatory bowel diseases. World J Gastroenterol. 2010; 16:4264-4271.
30. Guttman JA, Samji FN, Li Y, et al. Evidence that tight junctions are disrupted due to intimate bacterial contact and not inflammation during attaching and effacing pathogen infections in vivo. Infect Immun. 2006;74:6075-6084. (Pubitemid 44657385)
31. Hermiston ML, Gordon JI. In vivo analysis of cadherin function in the mouse intestinal epithelium: essential roles in adhesion, maintenance of differentiation, and regulation of programmed cell death. J Cell Biol. 1995;129:489-506.
32. Shao L, Serrano D, Mayer L. The role of epithelial cells in immune regulation in the gut. Semin Immunol. 2001;13:163-176.
33. Bruewer M, Luegering A, Kucharzik T, et al. Proinflammatory cytokines disrupt epithelial barrier function by apoptosisindependent mechanisms. J Immunol. 2003;171:6164-6172. (Pubitemid 37467239)
34. Dunlop SP, Hebden J, Campbell E, et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol. 2006;101:1288-1294. (Pubitemid 43829995)
35. Kerss S, Allen A, Garner A. A simple method for measuring thickness of the mucus gel layer adherent to rat, frog and human gastric mucosa: influence of feeding, prostaglandin, N-acetylcysteine and other agents. Clin Sci (Lond). 1982;63: 187-195. (Pubitemid 12000382)
36. Brown JF, Keates AC, Hanson PJ, et al. Nitric oxide generators and cGMP stimulate mucus secretion by rat gastric mucosal cells. Am J Physiol. 1993;265:G418-G422. (Pubitemid 23298275)
37. Atuma C, Strugala V, Allen A, et al. The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. Am J Physiol Gastrointest Liver Physiol. 2001;280:G922-G929.
38. Sababi M, Nilsson E, Holm L. Mucus and alkali secretion in the rat duodenum: effects of indomethacin, N omega-nitro-Larginine, and luminal acid. Gastroenterology. 1995;109: 1526-1534.
39. Schade C, Flemstrom G, Holm L. Hydrogen ion concentration in the mucus layer on top of acid-stimulated and-inhibited rat gastric mucosa. Gastroenterology. 1994;107:180-188. (Pubitemid 24195360)
40. Chu S, Tanaka S, Kaunitz JD, et al. Dynamic regulation of gastric surface pH by luminal pH. J Clin Invest. 1999;103: 605-612. (Pubitemid 29122413)
41. Jordan N, Newton J, Pearson J, et al. A novel method for the visualization of the in situ mucus layer in rat and man. Clin Sci (Lond). 1998;95:97-106. (Pubitemid 28370584)
42. Strugala V, Dettmar PW, Pearson JP, et al. Is the colonic mucus barrier multilayered (abstract)? Gastroenterology. 1999;116:G1395.
43. Walter E, Janich S, Roessler BJ, et al. HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: in vitro-in vivo correlation with permeability data from rats and humans. J Pharm Sci. 1996;85:1070-1076. (Pubitemid 26338920)
44. Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in postdysenteric irritable bowel syndrome. Gut. 2000;47:804-811.
45. Maxton DG, Bjarnason I, Reynolds AP, et al. Lactulose, 51Crlabelled ethylenediaminetetra-acetate, L-rhamnose and polyethyleneglycol 400 [corrected] as probe markers for assessment in vivo of human intestinal permeability. Clin Sci (Lond). 1986;71:71-80. (Pubitemid 16045225)
46. Bjarnason I, Peters TJ, Veall N. A persistent defect in intestinal permeability in coeliac disease demonstrated by a 51Cr-labelled EDTA absorption test. Lancet. 1983;1:323-325. (Pubitemid 13189171)
47. Hamilton I, Cobden I, Rothwell J, et al. Intestinal permeability in coeliac disease: the response to gluten withdrawal and singledose gluten challenge. Gut. 1982;23:202-210. (Pubitemid 12183731)
48. Vilela EG, Torres HO, Ferrari ML, et al. Gut permeability to lactulose and mannitol differs in treated Crohn's disease and celiac disease patients and healthy subjects. Braz J Med Biol Res. 2008;41:1105-1109.
49. Johnston SD, Smye M, Watson RP. Intestinal permeability tests in coeliac disease. Clin Lab. 2001;47:143-150. (Pubitemid 32236961)
50. Vilela EG, de Abreu Ferrari Mde L, de Gama Torres HO, et al. Intestinal permeability and antigliadin antibody test for monitoring adult patients with celiac disease. Dig Dis Sci. 2007; 52:1304-1309. (Pubitemid 46626182)
51. Arnott ID, Kingstone K, Ghosh S. Abnormal intestinal permeability predicts relapse in inactive Crohn disease. Scand J Gastroenterol. 2000;35:1163-1169.
52. Dastych M, Dastych M Jr, Novotna H, et al. Lactulose/mannitol test and specificity, sensitivity, and area under curve of intestinal permeability parameters in patients with liver cirrhosis and Crohn's disease. Dig Dis Sci. 2008;53:2789-2792.
53. Benjamin J, Makharia GK, Ahuja V, et al. Intestinal permeability and its association with the patient and disease characteristics in Crohn's disease. World J Gastroenterol. 2008;14:1399-1405. (Pubitemid 351425221)
54. D'Inca R, Di Leo V, Corrao G, et al. Intestinal permeability test as a predictor of clinical course in Crohn's disease. Am J Gastroenterol. 1999;94:2956-2960. (Pubitemid 29482764)
55. Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119: 15-22. (Pubitemid 30452574)
56. Teahon K, Somasundaram S, Smith T, et al. Assessing the site of increased intestinal permeability in coeliac and inflammatory bowel disease. Gut. 1996;38:864-869. (Pubitemid 26231771)
57. Ainsworth M, Eriksen J, Rasmussen JW, et al. Intestinal permeability of 51Cr-labelled ethylenediaminetetraacetic acid in patients with Crohn's disease and their healthy relatives. Scand J Gastroenterol. 1989;24:993-998.
58. Jenkins RT, Ramage JK, Jones DB, et al. Small bowel and colonic permeability to 51Cr-EDTA in patients with active inflammatory bowel disease. Clin Invest Med. 1988;11:151-155.
59. Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49:1877-1887.
60. Di Leo V, D'Inca R, Diaz-Granado N, et al. Lactulose/mannitol test has high efficacy for excluding organic causes of chronic diarrhea. Am J Gastroenterol. 2003;98:2245-2252. (Pubitemid 37305366)
61. Rao AS, Camilleri M, Eckert DJ, et al. Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhea and controls. Am J Physiol Gastrointest Liver Physiol. 2011;301:G919-G928.
62. Kiesslich R, Duckworth CA, Moussata D, et al. Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease. Gut. 2011;61: 1146-1153.
63. Wild GE, Waschke KA, Bitton A, et al. The mechanisms of prednisone inhibition of inflammation in Crohn's disease involve changes in intestinal permeability, mucosal TNFalpha production and nuclear factor kappa B expression. Aliment Pharmacol Ther. 2003;18:309-317. (Pubitemid 37046710)
64. Miki K, Moore DJ, Butler RN, et al. The sugar permeability test reflects disease activity in children and adolescents with inflammatory bowel disease. J Pediatr. 1998;133:750-754. (Pubitemid 28563943)
65. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond). 1998;94:557-572. (Pubitemid 28269054)
66. Goke MN, Schneider M, Beil W, et al. Differential glucocorticoid effects on repair mechanisms and NF-kappaB activity in the intestinal epithelium. Regul Pept. 2002;105:203-214. (Pubitemid 34311869)
67. Baumgart DC, Vierziger K, Sturm A, et al. Mesalamine promotes intestinal epithelial wound healing in vitro through a TGF-beta-independent mechanism. Scand J Gastroenterol. 2005;40:958-964. (Pubitemid 41117021)
68. Di Paolo MC, Merrett MN, Crotty B, et al. 5-Aminosalicylic acid inhibits the impaired epithelial barrier function induced by gamma interferon. Gut. 1996;38:115-119. (Pubitemid 26020936)
69. Suenaert P, Bulteel V, Lemmens L, et al. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol. 2002;97:2000-2004.
70. Rosenfeldt V, Benfeldt E, Valerius NH, et al. Effect of probiotics on gastrointestinal symptoms and small intestinal permeability in children with atopic dermatitis. J Pediatr. 2004;145:612-616. (Pubitemid 39440938)
71. Patel RM, Myers LS, Kurundkar AR, et al. Probiotic bacteria induce maturation of intestinal claudin 3 expression and barrier function. Am J Pathol. 2012;180:626-635.
72. Eun CS, Kim YS, Han DS, et al. Lactobacillus casei prevents impaired barrier function in intestinal epithelial cells. Apmis. 2011;119:49-56.
73. Garcia Vilela E, De Lourdes De Abreu Ferrari M, Oswaldo Da Gama Torres H, et al. Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission. Scand J Gastroenterol. 2008;43:842-848. (Pubitemid 351918523)
74. Copeman M, Matuz J, Leonard AJ, et al. The gastroduodenal mucus barrier and its role in protection against luminal pepsins: the effect of 16,16 dimethyl prostaglandin E2, carbopol-polyacrylate, sucralfate and bismuth subsalicylate. J Gastroenterol Hepatol. 1994;9(suppl 1):S55-S59.
75. Esteban Carretero J, Durban Reguera F, Lopez-Argueta Alvarez S, et al. A comparative analysis of response to vs. ORS+ gelatin tannate pediatric patients with acute diarrhea. Rev Esp Enferm Dig. 2009;101:41-48.